ClinicalTrials.Veeva

Menu

Ozurdex Endophtamitis Cohort, Prognostic Assessment at 12 Months

C

Centre Hospitalier Universitaire de Saint Etienne

Status

Enrolling

Conditions

Endophthalmitis

Treatments

Other: Analysis of retinograms
Other: Visual acuity analysis
Other: Intraocular pressure analysis
Other: Analysis of optical coherence tomography (OCT) images

Study type

Observational

Funder types

Other

Identifiers

NCT06268561
IRBN852023/CHUSTE

Details and patient eligibility

About

OZURDEX endophthalmitis is a rare and potentially very serious pathology. Different treatments can be carried out early and change the functional prognosis of the patient.

Enrollment

8 estimated patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patient who had endophtalmitis following an OZURDEX implant injection within 2 months

Exclusion criteria

  • Intra oculaire procedure in the interval between the injection of OZURDEX and endophtalmitis

Trial design

8 participants in 1 patient group

OZURDEX patients
Description:
Patients treated by Dr Garcin and Pr Thuret CHU of Saint Etienne in the context of post-OZURDEX endophthalmitis
Treatment:
Other: Analysis of optical coherence tomography (OCT) images
Other: Intraocular pressure analysis
Other: Visual acuity analysis
Other: Analysis of retinograms

Trial contacts and locations

1

Loading...

Central trial contact

Henri PITEAU, resident; Thibaud GARCIN, MD PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems